Entera Bio (ENTX) Chief R&D Gregory Burshtein Receives Award

What Happened Gregory Burshtein, Entera Bio's Chief of Research & Development, was granted 180,000 options to purchase ordinary shares (derivative award) reported on 2026-08-07. The reported acquisition price is $0.00 (no cash exchanged at grant). This was an equity compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: August 7, 2026 (grant reported the same day).
• Transaction type/code: Award/Grant (A); derivative security (options).
• Shares/options granted: 180,000 options; reported price $0.00.
• Shares owned after transaction: Not specified in the filing.
• Notable footnote: Grant was approved by the board on May 7, 2026, contingent on the Company filing a Form S-8; the S-8 was filed on Aug 7, 2026, enabling registration of the underlying shares.
• Vesting: Three-year vesting beginning May 7, 2026 — 1/3 vests May 7, 2027; remaining 2/3 vest ratably quarterly over the next two years. Full acceleration upon a Change in Control per the 2018 Equity Incentive Plan.
• Filing timeliness: Reported on the same date as the transaction; no late filing indicated.

Context This filing documents an option grant (compensation), which does not represent immediate ownership until options are exercised and may dilute existing shareholders if exercised. Grants are common for executives and are primarily a compensation/retention mechanism rather than a direct bullish or bearish trading signal.